PURPOSE OF REVIEW: Differential rates of disease progression are obviously multifactorial, but the virulence of the actual infecting virus is most frequently ignored as potential source of slow or rapid disease progression. In this review, the argument will be made that nearly all elite suppressors are infected by weak HIV-1 strain (in terms of replicative capacity). Whether this poor virus replication is the cause of elite suppression or the consequence of a strong immune response remains a leading question in the field. RECENT FINDINGS: Although numerous research studies have related HIV-1 replicative capacity/fitness in tissue culture to virulence within patients, this review will focus on several recent and key discoveries on the important role of HIV-1 fitness in elite suppression. First, elite suppressors appear to harbor HIV-1 variants that encode Gag, Pol, and Env proteins that are less efficient than their counterparts of HIV-1 in typical/chronic progressors. Second, the actual HIV-1 clone(s) that establish acute infection may be less fit in patients who become elite controllers as compared with typical progressors. Finally, the fitness costs of cytotoxic T lymphocyte escape in HIV-1 may be easily compensated by secondary mutations if the infecting strain is capable of high replication kinetics and rapid evolution. A strain with weak replicative capacity might not compensate for fitness loss or even generate the initial escape mutations. SUMMARY: A combination of good, anti-HIV-1 host genetics (e.g. HLA-B*57) along with infection by a 'whimpy' HIV-1 strain may be necessary for elite suppression, whereas only one of these may lead to slow progression and viremia.
PURPOSE OF REVIEW: Differential rates of disease progression are obviously multifactorial, but the virulence of the actual infecting virus is most frequently ignored as potential source of slow or rapid disease progression. In this review, the argument will be made that nearly all elite suppressors are infected by weak HIV-1 strain (in terms of replicative capacity). Whether this poor virus replication is the cause of elite suppression or the consequence of a strong immune response remains a leading question in the field. RECENT FINDINGS: Although numerous research studies have related HIV-1 replicative capacity/fitness in tissue culture to virulence within patients, this review will focus on several recent and key discoveries on the important role of HIV-1 fitness in elite suppression. First, elite suppressors appear to harbor HIV-1 variants that encode Gag, Pol, and Env proteins that are less efficient than their counterparts of HIV-1 in typical/chronic progressors. Second, the actual HIV-1 clone(s) that establish acute infection may be less fit in patients who become elite controllers as compared with typical progressors. Finally, the fitness costs of cytotoxic T lymphocyte escape in HIV-1 may be easily compensated by secondary mutations if the infecting strain is capable of high replication kinetics and rapid evolution. A strain with weak replicative capacity might not compensate for fitness loss or even generate the initial escape mutations. SUMMARY: A combination of good, anti-HIV-1 host genetics (e.g. HLA-B*57) along with infection by a 'whimpy' HIV-1 strain may be necessary for elite suppression, whereas only one of these may lead to slow progression and viremia.
Authors: Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson Journal: J Virol Date: 2010-05-05 Impact factor: 5.103
Authors: Bin Li; Adrianne D Gladden; Marcus Altfeld; John M Kaldor; David A Cooper; Anthony D Kelleher; Todd M Allen Journal: J Virol Date: 2006-10-25 Impact factor: 5.103
Authors: Koen K A Van Rompay; Tim B Matthews; Joanne Higgins; Don R Canfield; Ross P Tarara; Mark A Wainberg; Raymond F Schinazi; Niels C Pedersen; Thomas W North Journal: J Virol Date: 2002-06 Impact factor: 5.103
Authors: Samuel Alizon; Viktor von Wyl; Tanja Stadler; Roger D Kouyos; Sabine Yerly; Bernard Hirschel; Jürg Böni; Cyril Shah; Thomas Klimkait; Hansjakob Furrer; Andri Rauch; Pietro L Vernazza; Enos Bernasconi; Manuel Battegay; Philippe Bürgisser; Amalio Telenti; Huldrych F Günthard; Sebastian Bonhoeffer Journal: PLoS Pathog Date: 2010-09-30 Impact factor: 6.823
Authors: Roger Paredes; Manish Sagar; Vincent C Marconi; Rebecca Hoh; Jeffrey N Martin; Neil T Parkin; Christos J Petropoulos; Steven G Deeks; Daniel R Kuritzkes Journal: J Virol Date: 2008-11-19 Impact factor: 5.103
Authors: Toshiyuki Miura; Mark A Brockman; Arne Schneidewind; Michael Lobritz; Florencia Pereyra; Almas Rathod; Brian L Block; Zabrina L Brumme; Chanson J Brumme; Brett Baker; Alissa C Rothchild; Bin Li; Alicja Trocha; Emily Cutrell; Nicole Frahm; Christian Brander; Ildiko Toth; Eric J Arts; Todd M Allen; Bruce D Walker Journal: J Virol Date: 2008-12-30 Impact factor: 5.103
Authors: Zabrina L Brumme; Chun Li; Toshiyuki Miura; Jennifer Sela; Pamela C Rosato; Chanson J Brumme; Tristan J Markle; Eric Martin; Brian L Block; Alicja Trocha; Carl M Kadie; Todd M Allen; Florencia Pereyra; David Heckerman; Bruce D Walker; Mark A Brockman Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: Maria Salgado; Timothy P Brennan; Karen A O'Connell; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson Journal: Retrovirology Date: 2010-11-08 Impact factor: 4.602
Authors: Kara G Lassen; Michael A Lobritz; Justin R Bailey; Samantha Johnston; Sandra Nguyen; Benhur Lee; Tom Chou; Robert F Siliciano; Martin Markowitz; Eric J Arts Journal: PLoS Pathog Date: 2009-04-10 Impact factor: 6.823
Authors: Paul A Goepfert; Wendy Lumm; Paul Farmer; Philippa Matthews; Andrew Prendergast; Jonathan M Carlson; Cynthia A Derdeyn; Jianming Tang; Richard A Kaslow; Anju Bansal; Karina Yusim; David Heckerman; Joseph Mulenga; Susan Allen; Philip J R Goulder; Eric Hunter Journal: J Exp Med Date: 2008-04-21 Impact factor: 14.307
Authors: Mark A Brockman; Denis R Chopera; Alex Olvera; Chanson J Brumme; Jennifer Sela; Tristan J Markle; Eric Martin; Jonathan M Carlson; Anh Q Le; Rachel McGovern; Peter K Cheung; Anthony D Kelleher; Heiko Jessen; Martin Markowitz; Eric Rosenberg; Nicole Frahm; Jorge Sanchez; Simon Mallal; Mina John; P Richard Harrigan; David Heckerman; Christian Brander; Bruce D Walker; Zabrina L Brumme Journal: J Virol Date: 2012-04-11 Impact factor: 5.103
Authors: Catherine A Brennan; F Javier Ibarrondo; Catherine A Sugar; Mary Ann Hausner; Roger Shih; Hwee L Ng; Roger Detels; Joseph B Margolick; Charles R Rinaldo; John Phair; Lisa P Jacobson; Otto O Yang; Beth D Jamieson Journal: J Virol Date: 2012-07-18 Impact factor: 5.103
Authors: Xiaomei T Kuang; Xiaoguang Li; Gursev Anmole; Philip Mwimanzi; Aniqa Shahid; Anh Q Le; Louise Chong; Hua Qian; Toshiyuki Miura; Tristan Markle; Bemuluyigza Baraki; Elizabeth Connick; Eric S Daar; Heiko Jessen; Anthony D Kelleher; Susan Little; Martin Markowitz; Florencia Pereyra; Eric S Rosenberg; Bruce D Walker; Takamasa Ueno; Zabrina L Brumme; Mark A Brockman Journal: J Virol Date: 2014-06-25 Impact factor: 5.103
Authors: Ling Yue; Katja J Pfafferott; Joshua Baalwa; Karen Conrod; Catherine C Dong; Cecilia Chui; Rong Rong; Daniel T Claiborne; Jessica L Prince; Jianming Tang; Ruy M Ribeiro; Emmanuel Cormier; Beatrice H Hahn; Alan S Perelson; George M Shaw; Etienne Karita; Jill Gilmour; Paul Goepfert; Cynthia A Derdeyn; Susan A Allen; Persephone Borrow; Eric Hunter Journal: PLoS Pathog Date: 2015-01-08 Impact factor: 6.823
Authors: Jingyan Chen; Nadine Tibroni; Daniel Sauter; Johanna Galaski; Toshiyuki Miura; Galit Alter; Birthe Mueller; Claudia Haller; Bruce D Walker; Frank Kirchhoff; Zabrina L Brumme; Takamasa Ueno; Oliver T Fackler Journal: PLoS One Date: 2015-03-20 Impact factor: 3.240
Authors: Philip Mwimanzi; Tristan J Markle; Eric Martin; Yoko Ogata; Xiaomei T Kuang; Michiyo Tokunaga; Macdonald Mahiti; Florencia Pereyra; Toshiyuki Miura; Bruce D Walker; Zabrina L Brumme; Mark A Brockman; Takamasa Ueno Journal: Retrovirology Date: 2013-01-07 Impact factor: 4.602